Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Abstract Background The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in preclinical and early AD (mild cognit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri, Jeffrey Cummings
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-04-01
Colecção:	Alzheimer’s Research & Therapy
Assuntos:	Alzheimer’s disease Clinical trials Clinical meaningfulness Meaningful benefit Biomarkers Preclinical
Acesso em linha:	https://doi.org/10.1186/s13195-022-00984-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!